The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ORMP | -0.21% | -8.27% | -1.71% | +1,181% |
| S&P | +13.19% | +87.83% | +13.42% | +507% |
Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It focuses on the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in New York, NY.
The company's lead pipeline candidate is still being evaluated as a potential treatment for NASH after a major flop in treating type 2 diabetes.
The biotech's stock has been ripping higher of late.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.03M | 40.4% |
| Gross Margin | -0.85% | 0.0% |
| Market Cap | $108.25M | 8.8% |
| Market Cap / Employee | $8.33M | 0.0% |
| Employees | 13 | -13.3% |
| Net Income | $48.39M | 346.4% |
| EBITDA | -$2.40M | 21.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $52.18M | 23.9% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.59M | 216.7% |
| Short Term Debt | $0.27M | 11.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 22.75% | 20.5% |
| Return On Invested Capital | -11.21% | -0.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1.99M | 71.9% |
| Operating Free Cash Flow | -$1.99M | 71.9% |
| Metric | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 16.92 | 11.28 | 5.05 | 22.39 | - |
| Price to Book | 0.62 | 0.58 | 0.65 | 0.70 | 11.27% |
| Price to Sales | 69.61 | 180.07 | 44.11 | 47.94 | - |
| Price to Tangible Book Value | 0.62 | 0.58 | 0.65 | 0.70 | 11.27% |
| Enterprise Value to EBITDA | 12.07 | 10.26 | 17.50 | 0.88 | -94.24% |
| Return on Equity | -12.3% | -18.4% | -14.6% | 24.4% | 734.29% |
| Total Debt | $0.37M | $0.30M | $0.91M | $0.86M | 100.47% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
